Who is eligible for clinical trial NCT04556773?

Participants must meet protocol criteria for Metastatic Breast Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04556773 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-31

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (NCT04556773)

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

Who can join: Review the eligibility criteria below.

Location: Research Site — Commack, New York

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (37 Sites)

Showing the first 25 of 37 sites.

Research Site — Commack, New York
Research Site — Harrison, New York
Research Site — New York, New York
Research Site — New York, New York
Research Site — Uniondale, New York
Research Site — Chapel Hill, North Carolina
Research Site — Chattanooga, Tennessee
Research Site — Germantown, Tennessee
Research Site — Fort Worth, Texas
Research Site — Melbourne,
Research Site — Westmead,
Research Site — Edegem,
Research Site — Leuven,
Research Site — Ottignies,
Research Site — Goiânia,
Research Site — Porto Alegre,
Research Site — Porto Alegre,
Research Site — São Paulo,
Research Site — São Paulo,
Research Site — Kelowna, British Columbia
Research Site — Québec, Quebec
Research Site — Villejuif,
Research Site — Monterrey,
Research Site — Moscow,
Research Site — Moscow,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Breast Cancer

Assessing the Time Demands of Cancer — Birmingham, Alabama
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — Birmingham, Alabama
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor — Washington D.C., District of Columbia
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer — Tucson, Arizona
Roll-over Study to Allow Continued Access to Ribociclib — Chandler, Arizona

Explore by condition: All Metastatic Breast Cancer clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗